Veeda Clinical Research files DRHP for Rs 831 crore IPO
The issue will consist of the issuance of fresh equity shares worth up to Rs 331.60 crore and an offer for sale (OFS) of Rs 500 crore by promoters and existing shareholders
The issue will consist of the issuance of fresh equity shares worth up to Rs 331.60 crore and an offer for sale (OFS) of Rs 500 crore by promoters and existing shareholders
The company will leverage existing hospital and clinic partners’ infrastructure to build specialised `Experience Centres’ and facilitate a seamless, end-to-end secondary care surgery delivery. It will also offer healthcare financing
Zydus' Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
The startup’s AI platform uses AI algorithms to automatically detect abnormalities and diseases in medical images, reducing patient misdiagnosis and increasing radiologists’ productivity
The medicine helps restore the balance of certain natural substances (serotonin) in the brain
The amalgamation is expected to bring in a lot of synergies in terms of operational efficiency and productivity for the combined entity
The hospital through its network performs more than 10,000 joint replacement surgeries annually
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
The bioequivalence study was conducted by Accutest Research India, one of the preferred CRO players in India
The transactions resulted in a net cash inflow of Rs 183 crores for HCG in addition to the take-over of the labs and clinical research business
Subscribe To Our Newsletter & Stay Updated